Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Dosed First Patient in Phase 2 Trial
Oxford BioTherapeutics’s partner has dosed first patient in phase 2 trial that has potential to revolutionise treatment.
Oxford BioTherapeutics’s partner has dosed first patient in phase 2 trial that has potential to revolutionise treatment.
Wonderhood have been commissioned to produce a second season of Super Surgeons: A Chance at Life.
Laverock Therapeutics to demonstrate breadth of therapeutic applications of gene silencing platform at European Society of Gene & Cell Therapy.
Artificial Intelligence (AI), has emerged as a disruptive force with the potential to revolutionise industries across the globe. For investors and shareholders, AI represents a compelling opportunity.
Open Energy Market, Calculus portfolio company and a leading provider of energy procurement services and Net Zero technologies, has introduced a pioneering platform called True, which combines an organisation’s actual energy procurement costs with its Net Zero strategies.
Calculus has led an investment round into Laverock Therapeutics, a company developing a unique gene silencing platform for the creation of programmable advanced therapies.
Wonderhood Studios continue their stellar performance of signing household names as clients as part of their advertising business.
Maven Screen Media and Brouhaha continue progress.
Scancell achieve significant milestone for their cancer vaccine.
Calculus is delighted to launch the Calculus EIS Fund.